Last update 12 Dec 2025

MT-2990

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
MT 2990
Target
IL-33
Action
inhibitors
Mechanism
IL-33 inhibitors(Interleukin-33 inhibitors)
Therapeutic Areas
Immune System DiseasesNervous System DiseasesCardiovascular Diseases+ [3]
Active Indication
Churg-Strauss SyndromeGranulomatosis With PolyangiitisMicroscopic Polyangiitis
Inactive Indication
EndometriosisInflammationRhinitis, Allergic, Seasonal
Originator Organization
Mitsubishi Tanabe Pharma Corp.Mitsubishi Tanabe Pharma Corp.
Active Organization
Tanabe Pharma America, Inc.Tanabe Pharma America, Inc.
Inactive Organization
Mitsubishi Tanabe Pharma Corp.Mitsubishi Tanabe Pharma Corp.
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with MT-2990
NCT06196905
/ Active, not recruitingPhase 1
An Exploratory Study of MT-2990 in Patients With Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
NCT03840993
/ CompletedPhase 2
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women With Endometriosis Experiencing Endometrial Related Pain
NCT03570957
/ CompletedPhase 1
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (Single Dose Study)
100 Clinical Results associated with MT-2990
Login to view more data
100 Translational Medicine associated with MT-2990
Login to view more data
100 Patents (Medical) associated with MT-2990
Login to view more data
100 Deals associated with MT-2990
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EndometriosisPhase 2
United States
Tanabe Pharma America, Inc.Tanabe Pharma America, Inc.
15 Jan 2019
Churg-Strauss SyndromePhase 1
Japan
Tanabe Pharma America, Inc.Tanabe Pharma America, Inc.
24 Jun 2024
Granulomatosis With PolyangiitisPhase 1
Japan
Tanabe Pharma America, Inc.Tanabe Pharma America, Inc.
24 Jun 2024
Microscopic PolyangiitisPhase 1
Japan
Tanabe Pharma America, Inc.Tanabe Pharma America, Inc.
24 Jun 2024
Rhinitis, Allergic, SeasonalPhase 1
Japan
Tanabe Pharma America, Inc.Tanabe Pharma America, Inc.
17 Jul 2018
InflammationPhase 1
Netherlands
Mitsubishi Tanabe Pharma Corp.Mitsubishi Tanabe Pharma Corp.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03840993 (CTgov)
Phase 2
Endometriosis
76
Placebo
(Placebo)
xlrhcahjkq(kgistlposm) = yhzdfwjxxv ixbwxzctgo (seompcfsxx, 0.12)
View more
-
10 Jul 2024
(MT-2990)
xlrhcahjkq(kgistlposm) = wkfhvgxkjv ixbwxzctgo (seompcfsxx, 0.12)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free